Cargando…
Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
Many patients with systemic autoimmune rheumatic diseases (SARDs) require immunosuppression to reduce disease activity, but this also has important possible detrimental impacts on immune responses following vaccination. The phase III clinical trials for severe acute respiratory syndrome coronavirus...
Autores principales: | Paik, Julie J., Sparks, Jeffrey A., Kim, Alfred H.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058024/ https://www.ncbi.nlm.nih.gov/pubmed/35636384 http://dx.doi.org/10.1016/j.coph.2022.102243 |
Ejemplares similares
-
Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease
por: Robinson, Philip C., et al.
Publicado: (2021) -
Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions
por: Cavagna, Lorenzo, et al.
Publicado: (2014) -
Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022) -
Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy
por: Vanni, Kathleen MM, et al.
Publicado: (2022) -
The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review
por: Xie, Yan, et al.
Publicado: (2022)